Beta-cell Response to Incretin Hormones in Cystic Fibrosis
Recruiting
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has man... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Modulating Movement Intention Via Cortical Stimulation
Recruiting
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/28/2025
Locations: New York University School of Medicine, New York, New York
Conditions: Seizures, Seizure Disorder, Psychogenic Movement Disorder
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: BCG Oncology, Phoenix, Arizona +11 locations
Conditions: Urothelial Carcinoma, Bladder Cancer
International PPB/DICER1 Registry
Recruiting
Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which wil... Read More
Gender:
ALL
Ages:
Between 0 minutes and 100 years
Trial Updated:
01/28/2025
Locations: Children's Minnesota, Minneapolis, Minnesota
Conditions: Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
Recruiting
This study will prospectively collect airway, stool, and blood samples on 80 subjects with lung cancer undergoing immunotherapy. Investigators will evaluate airway/stool microbial signatures associated with local (lower airway) and systemic (blood) immune tone.They will then study whether microbiota and/or host signatures predict subjects' response by longitudinal assessment of the progression free survival. They will also repeat sampling after 8 weeks of immunotherapy to expand our mechanistic... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/28/2025
Locations: NYU Langone Health, New York, New York
Conditions: Lung Cancer
Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo
Recruiting
We aim to study the impact of perioperative IV lidocaine on postoperative pain control in patients undergoing paraesophageal hernia repair. This is in the context of an established ERAS protocol. We wish to study the effect of IV Lidocaine on postoperative short and long-term outcomes, including patients' length of stay postoperative mortality, morbidity, and quality of life. We will compare this to our standard pain management.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Atrium Health - Carolinas Medical Center, Charlotte, North Carolina
Conditions: Hernia, Paraesophageal
Spacer Graft Study
Recruiting
To determine which of three types of spacer grafts (hard palate vs autologous ear cartilage vs Enduragen) are the most effective in lower eyelid retraction repair outcomes as measured by MRD2 (margin to reflex distance 2)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Eyelid Diseases, Eyelid Droop
NIH R01 Friend to Friend With Coaching
Recruiting
This study examines the effectiveness of the Friend to Friend (F2F) program when conducted by teachers and counselors with active coaching from the research team. The project involves 14 small group sessions for relationally aggressive girls and 8 classroom sessions. Students, teachers, counselors and parents at intervention and control schools fill out pre- and post- program questionnaires.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Aggression
Intervention For AYAS With Cancer Risk Syndromes
Recruiting
This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making. * Over 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the U.S. every year and up to 10% have genetic changes (or, mutations) that put them at a higher risk of dev... Read More
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
01/28/2025
Locations: Emory University School of Medicine, Atlanta, Georgia +4 locations
Conditions: Cancer Risk Syndrome
Appalachian Partnership to Reduce Disparities (Aim 2)
Recruiting
By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically diverse GBMSM and transgender women in rural Appalachia. Study Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: HIV/AIDS, STI, HCV
Limb Occlusion Pressure Tourniquets to Decrease Pain After Surgery
Recruiting
Currently a standard tourniquet pressure is used for orthopedic surgeries. High tourniquet pressure had been associated with adverse side effects such as ischemia, muscle weakness, and post operative pain. Limb Occlusion Pressure, LOP, is based off the patient's systolic blood pressure plus a safety margin and is typically much lower than standard tourniquet pressure. The aim of this study is to determine if using LOP during orthopedic surgeries decreases post-operative pain and opioid consumpti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Limb Occlusion Pressure
A Study of DF6002 Alone and in Combination With Nivolumab
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of California Irvine, Orange, California +32 locations
Conditions: Solid Tumors